Next Article in Journal
GC-MS Analysis and Preliminary Antimicrobial Activity of Albizia adianthifolia (Schumach) and Pterocarpus angolensis (DC)
Previous Article in Journal
Characterization and Antimicrobial Activity of Volatile Constituents from Fresh Fruits of Alchornea cordifolia and Canthium subcordatum
Previous Article in Special Issue
Exosomes: Potential in Cancer Diagnosis and Therapy
Open AccessReview

The Changing Landscape of Breast Cancer: How Biology Drives Therapy

by 1,† and 2,*,†
1
Hematology Oncology, University of New Mexico Comprehensive Cancer Center, University of New Mexico, 1201 Camino de Salud N.E., MSC 07-4025, Albuquerque, NM 87131, USA
2
New Mexico Cancer Care Alliance, UNM Comprehensive Cancer Center Multidisciplinary Breast Cancer Clinic &Program, University of New Mexico, 1201 Camino de Salud N.E., MSC 07-4025, Albuquerque, NM 87131, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Daniel M.-Y. Sze and William Chi-shing Cho
Medicines 2016, 3(1), 2; https://doi.org/10.3390/medicines3010002
Received: 10 November 2015 / Revised: 4 January 2016 / Accepted: 7 January 2016 / Published: 21 January 2016
(This article belongs to the Special Issue Recent Advance in Targeted Therapy in Medicine)
Breast cancer is the most prevalent life-threatening cancer in women. Optimizing therapy to increase cure rates in early stage disease, and improving life expectancy and palliation for advanced stages, are goals driving major areas of research. The armamentarium of targeted treatments for breast cancer is ever expanding as understanding of breast cancer biology deepens. A revolution in our treatment was heralded a decade ago by the introduction of trastuzumab for human epidermal receptor-2 positive (HER2+) disease resulting in remarkable reductions in recurrence and improvements in overall survival (OS). Advances continue to be made in other breast cancer subtypes targeting key activating pathways for therapeutic development. However, for these other targeted agents, improvement in OS has been elusive. This article focuses on the development of targeted therapy in breast cancer focusing primarily on the last 5 years, to illustrate that as we understand the complex pathways allowing the dysregulated cell to become malignant, it also propels us closer towards the promise of precision and personalized medicine. View Full-Text
Keywords: breast cancer; targeted therapy; PI3K/AKT/mTOR Inhibitors; cyclin-dependent kinase (CDK) inhibitors; pertuzumab; Ado-trastruzumab-emtansine; angiogenesis inhibitors; poly (ADP-ribose) polymerases (PARP) inhibitors breast cancer; targeted therapy; PI3K/AKT/mTOR Inhibitors; cyclin-dependent kinase (CDK) inhibitors; pertuzumab; Ado-trastruzumab-emtansine; angiogenesis inhibitors; poly (ADP-ribose) polymerases (PARP) inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

Friend, S.; Royce, M. The Changing Landscape of Breast Cancer: How Biology Drives Therapy. Medicines 2016, 3, 2. https://doi.org/10.3390/medicines3010002

AMA Style

Friend S, Royce M. The Changing Landscape of Breast Cancer: How Biology Drives Therapy. Medicines. 2016; 3(1):2. https://doi.org/10.3390/medicines3010002

Chicago/Turabian Style

Friend, Sarah; Royce, Melanie. 2016. "The Changing Landscape of Breast Cancer: How Biology Drives Therapy" Medicines 3, no. 1: 2. https://doi.org/10.3390/medicines3010002

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop